Murwere wegomarara repfungwa, uyo akadzoka kuchirwere mushure mekurapwa kweCAR-T ka17, akaona bundu rake richinyangarika zvachose mukati memavhiki mana mushure mekugamuchira mushonga mutsva weTIL uye akaramba asina bundu kwemwedzi inopfuura makumi maviri.
Kana muchida kubvunza nezve mishonga mitsva yegomarara uye miedzo yekiriniki:
Nhare: 4008803716 | WeChat: 17801183037| Email ：100085_010@163.com
Murwere wechirume ane makore makumi mashanu nematanhatu ekuberekwa akaonekwa aine chirwere chegomarara rekuruboshwe (left frontal lobe glioblastoma) (IDH wild-type, WHO Grade 4, EGFR amplification)—chimwe chezvirwere zvegomarara remuuropi zvakanyanya uye zvakaoma kurapa.
Mushure mekuvhiyiwa bundu musi wa5 Ndira 2023, pakutanga akapihwa kurapwa kwakajairika, asi chirwere chake chakadzoka mushure menguva pfupi yekugadzikana. Mushure mezvo, akaongororwa CAR-T ka17 achitarisa maantigen maviri akasiyana, asi chirwere chake chakaramba chichienderera mberi.
Apererwa nezano, akanyoresa muchirongwa chekurapa kweTIL. Mhedzisiro yacho yaishamisa: mavhiki mana chete mushure mekuiswa TIL cell, kuongororwa kwemifananidzo kwakaratidza kuti bundu muuropi hwake rakanga rabviswa zvachose, zvichiita kuti apindure zvizere, uye akaramba asina bundu kwemwedzi inopfuura makumi maviri.
—
Kurwira Kupona Mumamiriro Ezvinhu Asina Kunaka
Glioblastoma inozivikanwa se "muurayi mukuru wepfungwa." Nguva yekuongororwa kwechirwere inonzwa sekutanga kwekuverengera hupenyu hwemunhu.
Mushure mekuongororwa kwaVaW, vakatanga vavhiyiwa gomarara remuuropi rine njodzi huru, vakazoteverwa nekurapwa nemishonga inonzi temozolomide chemotherapy uye radiotherapy. Zvisinei, mamiriro avo haana kudzorwa.
Mushure mezvo, akaedza nzira mbiri dzakasiyana dzekurapa dzeCAR-T achitarisa maantigen akasiyana, achibayiwa majekiseni anopfuura gumi mukati meganda pamwe chete, asi izvi zvakakundikana kumisa kufambira mberi kwegomarara.
Kurapa kwechivanhu hakushandi zvakanaka pakurapa glioma yeuropi. Kunyangwe paine zvirongwa zvekurapa zvakabatana zvinosanganisira kuvhiyiwa, radiotherapy, uye chemotherapy, avhareji yekurarama kwevarwere ndeyemwedzi 14.6 chete.
Vachitarisana nemamiriro ezvinhu asina tariro akadaro, VaW nemhuri yavo vakanzwa kuora mwoyo kukuru kusvika vaziva nezvekuedzwa kwekiriniki kweTIL therapy.
Kurapa kweTIL
Kurapa kweTIL, kana kuti Tumor-Infiltrating Lymphocyte therapy, inzira itsva yekurapa nekudzivirira zvirwere mumasero.
Kurapa uku kunotanga nenyama itsva yegomarara remurwere sezvinhu zvitsva. Mushure mekupatsanurwa, kugadziriswa, uye kukura mu vitro, masero anodzoserwa mumurwere, zvichiita kuti kurapwa kwacho "kurwe negomarara iri roga."
Kusiyana nekurapa kweCAR-T kwechinyakare, kurapwa kweGC101 TIL hakudi lymphodepletion kana jekiseni reIL-2, zvichiwedzera kuchengetedzeka uye nyore kurapwa.
Yakagadzirwa neJuncell Therapeutics, GC101 TIL therapy ndiyo yekutanga pasi rose yeTIL therapy isingade lymphodepletion kana jekiseni reIL-2, ichishandisa puratifomu yayo yekuwedzera masero eDeepTIL® yakazvigadzira.
Ruzivo rwekiriniki rwuripo runoratidza kuti GC101 ine mukana wekupindura wakananga unodarika 35% kana ichienzaniswa nemarudzi akasiyana-siyana emagomarara akasimba. Varwere vakati wandei vakakwanisa kubvisa gomarara rose uye kupindura kwaro zvizere, uye nguva refu kwazvo yekupona isina gomarara inodarika makore matatu.
Maitiro Ekurapa
Pakupera kwegore ra2023, VaW vakabudirira kunyoresa muchirongwa chekurapa cheGC101 TIL.
Chikwata chekurapa chakashandisa masero eTIL akamera kubva mumuenzaniso wake wekuvhiya waakawana gore rapfuura, ayo akanga acheneswa kusvika adikanwa.
Chikwata chekurapa chakabudirira kuwedzera masero kusvika pamasero ese e2.95 × 10^10 TIL, nemasero eT achiverengera 99.92% yevanhu, akawanda acho ari CD8⁺ T-cells (97.85%).
Mushure mekugadziriswa kwemuviri, VaW vakapinzwa TIL cell infusion musi wa12 Zvita 2023.
Panguva yekuisirwa mushonga, VaW havana kusangana nematambudziko akanyanya, asi fivha shoma yakadzikira nekukurumidza. Zvichienzaniswa nemishonga yechinyakare yeTIL, iyi shanduro yakagadziriswa yakaratidza kuchengetedzeka kwakanyanya.
Kuchinja Kunoshamisa
Mavhiki mana chete mushure mekuiswa kweTIL cell, kuongororwa kwemifananidzo musi wa8 Ndira 2024, kwakaratidza kuti bundu raiva muuropi hwaVaW rakanga rabviswa zvachose.
Zvinotoshamisa ndezvokuti, kubva muna Gumiguru 2025, murwere uyu agara asina bundu kwemakore anopfuura 1.8 (zvichiverengerwa panguva yekuburitswa kwenhau, izvi zvinodarika mwedzi makumi maviri), achidzoka muhupenyu hwakajairika.
Nyaya iyi inoisa rekodhi itsva yekupona kweglioblastoma inodzokororwa uye inopa humbowo hwakakosha hwekurapa kwe "kutanga kwekuyedzwa kwetishu, TIL reinfusion kana yadzokororwa."
Kubudirira uku kunoshamisa kucharatidzwa muposita paMusangano weGore negore wechi40 weSociety for Immunotherapy of Cancer, uchaitwa kubva muna Mbudzi 7-9, 2025, uchiratidzwa kune nyanzvi dzeindasitiri yepasi rose.
Tarisiro Yeramangwana
Kurapa kweTIL kwakaratidza kugona kwete chete mukurapa glioma yeuropi asiwo kwakaratidza kushanda kwakanaka pakurwisa mamwe mabundu akaoma sekenza ye melanoma uye kenza yemapapu isiri diki.
Muna Kukadzi 2024, mushonga wekutanga weTIL cell therapy pasi rose, Lifileucel, wakagamuchira mvumo yeFDA muUnited States yekurapa varwere vane melanoma yakakwira vakambogamuchira mushonga wePD-1 inhibitor.
Panguva imwe chete, China iri kufambira mberi nekutsvaga kwekiriniki pakurapa kweTIL. Kuedzwa kwakakosha kwekiriniki kwechikamu chechipiri cheJuncell Therapeutics's GC101 TIL injection inotarisa advanced melanoma kwakatenderwa neCenter for Drug Evaluation yeNational Medical Products Administration.
Uyezve, musi wa14 Gumiguru, 2024, kuyedzwa kwekutanga kwekunyoreswa kwemishonga yeTIL cell muChina kwakagadzirirwa kurapa kenza yemapapu isina kukura.
—
Parizvino, kuchine miedzo yakawanda yekurapa yemishonga mitsva yekurwisa kenza uye matekinoroji muChina ari kutsvaga varwere.
Dhipatimendi reBeijing South Region Oncology Hospital International rinopa mazano pamusoro pemishonga mitsva netekinoroji.
Nhamba yefoni: 4008803716
Nhamba yeWeChat: 17801183037
Email ①: 100085_010@163.com
Email ②: myimmnet@163.com
Nguva yekutumira: Mbudzi-20-2025